

Phase I Study of the Intravenous Administration of Atte Patients With Metastatic Melanoma

Journal of Clinical Oncology

20, 142-152

DOI: [10.1200/jco.20.1.142](https://doi.org/10.1200/jco.20.1.142)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Tumor Microenvironment and the Response to Anticancer Therapy. <i>Cancer Biology and Therapy</i> , 2002, 1, 453-458.	1.5	215
2	Antitumor Effects in Mice of the Intravenous Injection of Attenuated Salmonella Typhimurium. <i>Journal of Immunotherapy</i> , 2002, 25, 218-225.	1.2	67
3	Tumor-Targeted Salmonella Expressing Cytosine Deaminase as an Anticancer Agent. <i>Human Gene Therapy</i> , 2002, 13, 1225-1233.	1.4	107
4	Opinion and Evidence in Cancer. <i>American Journal of Cancer</i> , 2002, 1, 153-163.	0.4	0
5	Live bacteria as the basis for immunotherapies against cancer. <i>Expert Review of Vaccines</i> , 2002, 1, 495-505.	2.0	39
6	Bugs as drugs for cancer. <i>Immunology</i> , 2002, 107, 10-19.	2.0	19
7	Raf kinases in lung tumor development. <i>Advances in Enzyme Regulation</i> , 2003, 43, 183-195.	2.9	18
8	Pilot trial of genetically modified, attenuated Salmonella expressing the E. coli cytosine deaminase gene in refractory cancer patients. <i>Cancer Gene Therapy</i> , 2003, 10, 737-744.	2.2	277
9	Clostridia in cancer therapy. <i>Nature Reviews Microbiology</i> , 2003, 1, 237-242.	13.6	137
10	Bacteria as tumour-targeting vectors. <i>Lancet Oncology</i> , The, 2003, 4, 548-556.	5.1	257
11	Immunotherapy of Malignant Diseases. <i>International Archives of Allergy and Immunology</i> , 2003, 132, 294-309.	0.9	31
12	Non-invasive 19F MR spectroscopy of 5-fluorocytosine to 5-fluorouracil conversion by recombinant Salmonella in tumours. <i>British Journal of Cancer</i> , 2003, 89, 1796-1801.	2.9	36
13	Salmonella enterica Serovar Typhimurium Expressing Mutant Lipid A with Decreased Endotoxicity Causes Maturation of Murine Dendritic Cells. <i>Infection and Immunity</i> , 2003, 71, 6132-6140.	1.0	16
14	Tumor-Specific Gene Delivery Using Genetically Engineered Bacteria. <i>Current Gene Therapy</i> , 2003, 3, 207-221.	0.9	48
15	New prognostic factors and developing therapy of cutaneous melanoma. <i>Annals of Medicine</i> , 2003, 35, 66-78.	1.5	14
16	Continuous Intravenous Administration of Live Genetically Modified Salmonella Typhimurium in Patients With Metastatic Melanoma. <i>Journal of Immunotherapy</i> , 2003, 26, 179-180.	1.2	134
18	Bacteria and Bacterial Toxins as Therapeutic Agents for Solid Tumors. <i>Current Cancer Drug Targets</i> , 2004, 4, 689-702.	0.8	46
19	Exploiting tumour hypoxia in cancer treatment. <i>Nature Reviews Cancer</i> , 2004, 4, 437-447.	12.8	2,406

#	ARTICLE	IF	CITATIONS
20	Potential therapeutic applications of recombinant, invasive E. coli. <i>Gene Therapy</i> , 2004, 11, 1224-1233.	2.3	69
21	Nosocomial nontyphoidal salmonellosis after antineoplastic chemotherapy: reactivation of asymptomatic colonization?. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2004, 23, 751-758.	1.3	22
22	M cell targeting with Aleuria aurantia lectin as a novel approach for oral allergen immunotherapy. <i>Journal of Allergy and Clinical Immunology</i> , 2004, 114, 1362-1368.	1.5	60
23	Positron emission tomography (PET) imaging of tumor-localized Salmonella expressing HSV1-TK. <i>Cancer Gene Therapy</i> , 2005, 12, 101-108.	2.2	78
24	Cancer immunotherapy based on the killing of Salmonella typhimurium-infected tumour cells. <i>Expert Opinion on Biological Therapy</i> , 2005, 5, 443-449.	1.4	14
25	Pharmacologic and Toxicologic Evaluation of C. novyi-NT Spores. <i>Toxicological Sciences</i> , 2005, 88, 562-575.	1.4	90
26	Systemic Administration of an Attenuated, Tumor-Targeting Salmonella typhimurium to Dogs with Spontaneous Neoplasia: Phase I Evaluation. <i>Clinical Cancer Research</i> , 2005, 11, 4827-4834.	3.2	147
27	Tumor-targeting bacterial therapy with amino acid auxotrophs of GFP-expressing Salmonella typhimurium. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 755-760.	3.3	439
28	Enhanced therapeutic effect by combination of tumor-targeting salmonella and endostatin in murine melanoma model. <i>Cancer Biology and Therapy</i> , 2005, 4, 840-845.	1.5	51
29	Cancer Immunotherapy Based on Killing of Salmonella-Infected Tumor Cells. <i>Cancer Research</i> , 2005, 65, 3920-3927.	0.4	157
30	Systemic administration of attenuated Salmonella choleraesuis in combination with cisplatin for cancer therapy. <i>Molecular Therapy</i> , 2005, 11, 707-716.	3.7	74
31	Short hairpin RNA expressing bacteria elicit RNA interference in mammals. <i>Nature Biotechnology</i> , 2006, 24, 697-702.	9.4	239
32	Recombinant Escherichia coli Expressing Invasin Targets the Peyer's Patches: the Basis for a Bacterial Formulation for Oral Vaccination. <i>Molecular Therapy</i> , 2006, 14, 183-191.	3.7	40
33	Clostridium spores as anti-tumour agents. <i>Trends in Microbiology</i> , 2006, 14, 190-196.	3.5	69
34	Bacterial gene therapy strategies. <i>Journal of Pathology</i> , 2006, 208, 290-298.	2.1	121
35	Bacteria in gene therapy: bactofection versus alternative gene therapy. <i>Gene Therapy</i> , 2006, 13, 101-105.	2.3	94
36	Salmonella typhimurium specifically chemotax and proliferate in heterogeneous tumor tissue in vitro. <i>Biotechnology and Bioengineering</i> , 2006, 94, 710-721.	1.7	173
37	Use of bacteria in anti-cancer therapies. <i>BioEssays</i> , 2006, 28, 84-94.	1.2	72

#	ARTICLE	IF	CITATIONS
38	Therapeutic biology: Checkpoint pathway activation therapy, HIV Tat, and transkingdom RNA interference. <i>Journal of Cellular Physiology</i> , 2006, 209, 695-700.	2.0	7
39	Immunotherapy for patients with malignant glioma: from theoretical principles to clinical applications. <i>Expert Review of Neurotherapeutics</i> , 2006, 6, 1481-1494.	1.4	24
40	Anti-tumor Immunotherapy via Antigen Delivery from a Live Attenuated Genetically Engineered <i>Pseudomonas aeruginosa</i> Type III Secretion System-Based Vector. <i>Molecular Therapy</i> , 2006, 14, 656-661.	3.7	46
41	Targeted Therapy with a <i>Salmonella Typhimurium</i> Leucine-Arginine Auxotroph Cures Orthotopic Human Breast Tumors in Nude Mice. <i>Cancer Research</i> , 2006, 66, 7647-7652.	0.4	278
42	Monotherapy with a tumor-targeting mutant of <i>Salmonella typhimurium</i> cures orthotopic metastatic mouse models of human prostate cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 10170-10174.	3.3	229
43	Immunotherapy of Cancer. , 2007, , 211-235.		3
44	Attenuated <i>Salmonella</i> engineered to produce human cytokine LIGHT inhibit tumor growth. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 12879-12883.	3.3	153
45	Recent Patents on Bacterial Proteins as Potential Anticancer Agents. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2007, 2, 224-234.	0.8	9
46	Improving tumor targeting and therapeutic potential of <i>Salmonella</i> VNP20009 by displaying cell surface CEA-specific antibodies. <i>Vaccine</i> , 2007, 25, 4183-4192.	1.7	69
47	Facultative or obligate anaerobic bacteria have the potential for multimodality therapy of solid tumours. <i>European Journal of Cancer</i> , 2007, 43, 490-496.	1.3	87
48	Tumor Hypoxia in Cancer Therapy. <i>Methods in Enzymology</i> , 2007, 435, 295-321.	0.4	254
49	General Principles of Tumor Immunotherapy. , 2007, , .		3
50	Development of <i>Salmonella</i> Strains as Cancer Therapy Agents and Testing in Tumor Cell Lines. <i>Methods in Molecular Biology</i> , 2007, 394, 323-354.	0.4	17
51	<i>Salmonella</i> . <i>Methods in Molecular Biology</i> , 2007, 394, v-vi.	0.4	7
52	Tumor-targeting <i>Salmonella typhimurium</i> improves cyclophosphamide chemotherapy at maximum tolerated dose and low-dose metronomic regimens in a murine melanoma model. <i>International Journal of Cancer</i> , 2007, 121, 666-674.	2.3	56
53	Live attenuated <i>Salmonella</i> as a vector for oral cytokine gene therapy in melanoma. <i>Journal of Gene Medicine</i> , 2007, 9, 416-423.	1.4	63
54	In vivo gene regulation in <i>Salmonella</i> spp. by a salicylate-dependent control circuit. <i>Nature Methods</i> , 2007, 4, 937-942.	9.0	84
55	Oral delivery of tumor-targeting <i>Salmonella</i> for cancer therapy in murine tumor models. <i>Cancer Science</i> , 2007, 98, 1107-1112.	1.7	54

#	ARTICLE	IF	CITATIONS
56	Bacterial proteins and CpG-rich extrachromosomal DNA in potential cancer therapy. <i>Plasmid</i> , 2007, 57, 4-17.	0.4	25
57	Attenuated <i>Salmonella typhimurium</i> with IL-2 Gene Reduces Pulmonary Metastases in Murine Osteosarcoma. <i>Clinical Orthopaedics and Related Research</i> , 2008, 466, 1285-1291.	0.7	49
58	Intra-tumoral <i>Salmonella typhimurium</i> induces a systemic anti-tumor immune response that is directed by low-dose radiation to treat distal disease. <i>European Journal of Immunology</i> , 2008, 38, 1937-1947.	1.6	43
59	Establishment and characterization of conditions required for tumor colonization by intravenously delivered bacteria. <i>Biotechnology and Bioengineering</i> , 2008, 100, 567-578.	1.7	46
60	Bacterial therapies: completing the cancer treatment toolbox. <i>Current Opinion in Biotechnology</i> , 2008, 19, 511-517.	3.3	70
61	Attenuated Bacteria as Effectors in Cancer Immunotherapy. <i>Annals of the New York Academy of Sciences</i> , 2008, 1138, 351-357.	1.8	32
62	Genetic detoxification of anarA <i>Salmonella entericaserovar Typhimurium</i> vaccine strain does not compromise protection against virulent <i>Salmonella</i> and enhances the immune responses towards a protective malarial antigen. <i>FEMS Immunology and Medical Microbiology</i> , 2008, 52, 237-246.	2.7	14
63	IL-18-producing <i>Salmonella</i> inhibit tumor growth. <i>Cancer Gene Therapy</i> , 2008, 15, 787-794.	2.2	105
64	Suicide gene/prodrug therapy using salmonella-mediated delivery of <i>Escherichia coli</i> purine nucleoside phosphorylase gene and 6-methoxypurine 2 ^{deoxyribose} in murine mammary carcinoma 4T1 model. <i>Cancer Science</i> , 2008, 99, 1172-1179.	1.7	27
65	Attenuated <i>Salmonella typhimurium</i> with interleukin 2 gene prevents the establishment of pulmonary metastases in a model of osteosarcoma. <i>Journal of Pediatric Surgery</i> , 2008, 43, 1153-1158.	0.8	43
66	Bacterial targeted tumour therapy-dawn of a new era. <i>Cancer Letters</i> , 2008, 259, 16-27.	3.2	140
67	Inhibition of Tumor Growth Using <i>Salmonella</i> Expressing Fas Ligand. <i>Journal of the National Cancer Institute</i> , 2008, 100, 1113-1116.	3.0	92
68	<i>Escherichia coli</i> Nissle 1917 Facilitates Tumor Detection by Positron Emission Tomography and Optical Imaging. <i>Clinical Cancer Research</i> , 2008, 14, 2295-2302.	3.2	82
69	<i>Salmonella typhimurium</i> as a novel RNA interference vector for cancer gene therapy. <i>Cancer Biology and Therapy</i> , 2008, 7, 152-153.	1.5	3
70	Genetic immunization: Bacteria as DNA vaccine delivery vehicles. <i>Hum Vaccin</i> , 2008, 4, 189-202.	2.4	32
71	Promises and challenges for the development of <i>Listeria monocytogenes</i> -based immunotherapies. <i>Expert Review of Vaccines</i> , 2008, 7, 1069-1084.	2.0	45
72	Attenuated <i>Salmonella</i> Targets Prodrug Activating Enzyme Carboxypeptidase G2 to Mouse Melanoma and Human Breast and Colon Carcinomas for Effective Suicide Gene Therapy. <i>Clinical Cancer Research</i> , 2008, 14, 4259-4266.	3.2	78
73	<i>Salmonella</i> Promoters Preferentially Activated Inside Tumors. <i>Cancer Research</i> , 2008, 68, 4827-4832.	0.4	73

#	ARTICLE	IF	CITATIONS
74	Therapeutic targeting of tumors with imageable GFP-expressing Salmonella typhimurium auxotrophic mutants. , 2008, , .		1
75	Transkingdom RNA interference (tkRNAi) as a new delivery tool for therapeutic RNA. Expert Opinion on Biological Therapy, 2009, 9, 1533-1542.	1.4	5
76	Systemic targeting of primary bone tumor and lung metastasis of high-grade osteosarcoma in nude mice with a tumor-selective strain of Salmonella typhimurium. Cell Cycle, 2009, 8, 870-875.	1.3	113
77	msbB deletion confers acute sensitivity to CO ₂ in Salmonella enterica serovar Typhimurium that can be suppressed by a loss-of-function mutation in zwf. BMC Microbiology, 2009, 9, 170.	1.3	12
78	Potent anti-tumor activity of systemically-administered IL2-expressing Salmonella correlates with decreased angiogenesis and enhanced tumor apoptosis. Clinical Immunology, 2009, 130, 89-97.	1.4	87
79	Novel cancer vaccine based on genes of Salmonella pathogenicity island 2. International Journal of Cancer, 2010, 126, 2622-2634.	2.3	80
80	Cancer metastasis directly eradicated by targeted therapy with a modified Salmonella typhimurium. Journal of Cellular Biochemistry, 2009, 106, 992-998.	1.2	125
81	Toward general prophylactic cancer vaccination. BioEssays, 2009, 31, 1071-1079.	1.2	15
82	Tumor-targeting amino acid auxotrophic Salmonella typhimurium. Amino Acids, 2009, 37, 509-521.	1.2	32
83	Recombinant E. coli LLO/OVA vaccination effectively inhibits murine melanoma metastasis to lung by CD8+T cells immunity. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2009, 21, 44-49.	0.7	2
84	Salmonella typhimurium engineered to produce CCL21 inhibit tumor growth. Cancer Immunology, Immunotherapy, 2009, 58, 769-775.	2.0	101
85	Bacterial delivery of a novel cytolysin to hypoxic areas of solid tumors. Gene Therapy, 2009, 16, 329-339.	2.3	154
86	Tumour-targeted delivery of TRAIL using Salmonella typhimurium enhances breast cancer survival in mice. British Journal of Cancer, 2009, 101, 1683-1691.	2.9	152
87	The first clinical use of a live-attenuated Listeria monocytogenes vaccine: A Phase I safety study of Lm-LLO-E7 in patients with advanced carcinoma of the cervix. Vaccine, 2009, 27, 3975-3983.	1.7	271
88	Chapter 13 Tumor-Specific Liposomal Drug Release Mediated by Liposomase. Methods in Enzymology, 2009, 465, 251-265.	0.4	13
89	Biological Gene Delivery Vehicles: Beyond Viral Vectors. Molecular Therapy, 2009, 17, 767-777.	3.7	282
90	Humoral Immune Responses Inhibit the Antitumor Activities Mediated by Salmonella enterica Serovar choleraesuis. Journal of Immunotherapy, 2009, 32, 376-388.	1.2	24
91	Salmonella as Live Trojan Horse for Vaccine Development and Cancer Gene Therapy. Current Gene Therapy, 2010, 10, 56-76.	0.9	59

#	ARTICLE	IF	CITATIONS
92	Editorial [Hot Topic: Bacterial Vectors for Gene & Cell Therapy (Guest Editors: Mark Tangney & Tj ETQq0 0,9 rgBT /QOverlock 1	0.0	0
93	Salmonellaâ€”allies in the fight against cancer. <i>Journal of Molecular Medicine</i> , 2010, 88, 763-773.	1.7	83
94	Molecular Imaging of Biological Gene Delivery Vehicles for Targeted Cancer Therapy: Beyond Viral Vectors. <i>Nuclear Medicine and Molecular Imaging</i> , 2010, 44, 15-24.	0.6	17
95	Cancer immunoediting and â€”spontaneousâ€”tumor regression. <i>Pathology Research and Practice</i> , 2010, 206, 1-8.	1.0	49
96	Targeting solid tumors with nonâ€”pathogenic obligate anaerobic bacteria. <i>Cancer Science</i> , 2010, 101, 1925-1932.	1.7	62
97	Targeted therapy of spinal cord glioma with a genetically modified <i>Salmonella typhimurium</i> . <i>Cell Proliferation</i> , 2010, 43, 41-48.	2.4	100
98	An enteric pathogen <i>Salmonella enterica</i> serovar Typhimurium suppresses tumor growth by downregulating CD44 ^{high} and CD4T regulatory (Treg) cell expression in mice: the critical role of lipopolysaccharide and Braun lipoprotein in modulating tumor growth. <i>Cancer Gene Therapy</i> , 2010, 17, 97-108.	2.2	32
99	Engineering the perfect (bacterial) cancer therapy. <i>Nature Reviews Cancer</i> , 2010, 10, 785-794.	12.8	648
101	Safety and immunogenicity of <i>Salmonella typhimurium</i> expressing C-terminal truncated human IL-2 in a murine model. <i>Biologics: Targets and Therapy</i> , 2010, 4, 61.	3.0	9
102	Virulence, Inflammatory Potential, and Adaptive Immunity Induced by <i>Shigella flexneri</i> msbB Mutants. <i>Infection and Immunity</i> , 2010, 78, 400-412.	1.0	40
103	High-Throughput Screening for <i>Salmonella</i> Avirulent Mutants That Retain Targeting of Solid Tumors. <i>Cancer Research</i> , 2010, 70, 2165-2170.	0.4	46
104	Vessel destruction by tumor-targeting <i>Salmonella typhimurium</i> A1-R is enhanced by high tumor vascularity. <i>Cell Cycle</i> , 2010, 9, 4518-4524.	1.3	99
105	Bacteria as tumor therapeutics?. <i>Bioengineered Bugs</i> , 2010, 1, 146-147.	2.0	41
106	Targeted Enzyme Prodrug Therapies. <i>Mini-Reviews in Medicinal Chemistry</i> , 2010, 10, 887-904.	1.1	81
107	Tumour Targeting with Systemically Administered Bacteria. <i>Current Gene Therapy</i> , 2010, 10, 3-14.	0.9	83
108	Myristoylation negative msbB-mutants of probiotic <i>E. coli</i> Nissle 1917 retain tumor specific colonization properties but show less side effects in immunocompetent mice. <i>Bioengineered Bugs</i> , 2010, 1, 139-145.	2.0	13
109	Bacteria as vectors for gene therapy of cancer. <i>Bioengineered Bugs</i> , 2010, 1, 385-394.	2.0	139
110	Enterobacterial tumor colonization in mice depends on bacterial metabolism and macrophages but is independent of chemotaxis and motility. <i>International Journal of Medical Microbiology</i> , 2010, 300, 449-456.	1.5	59

#	ARTICLE	IF	CITATIONS
111	Monotherapy with a Tumor-Targeting Mutant of <i>S. typhimurium</i> Inhibits Liver Metastasis in a Mouse Model of Pancreatic Cancer. <i>Journal of Surgical Research</i> , 2010, 164, 248-255.	0.8	125
112	Tumor-targeted delivery of biologically active TRAIL protein. <i>Cancer Gene Therapy</i> , 2010, 17, 334-343.	2.2	31
113	Gene therapy for cancer: bacteria-mediated anti-angiogenesis therapy. <i>Gene Therapy</i> , 2011, 18, 425-431.	2.3	50
114	Approaches in Gene Therapy of Cancer and Cardiovascular Diseases. , 0, , .		3
115	Association of attenuated mutants of <i>Salmonella enterica</i> serovar Enteritidis with porcine peripheral blood leukocytes. <i>FEMS Microbiology Letters</i> , 2011, 321, 37-42.	0.7	4
116	Influence of infection route and virulence factors on colonization of solid tumors by <i>Salmonella enterica</i> serovar Typhimurium. <i>FEMS Immunology and Medical Microbiology</i> , 2011, 62, 75-83.	2.7	58
117	In tumors <i>Salmonella</i> migrate away from vasculature toward the transition zone and induce apoptosis. <i>Cancer Gene Therapy</i> , 2011, 18, 457-466.	2.2	134
118	Tumor-seeking <i>Salmonella</i> amino acid auxotrophs. <i>Current Opinion in Biotechnology</i> , 2011, 22, 917-923.	3.3	46
119	Bio-inspired, bioengineered and biomimetic drug delivery carriers. <i>Nature Reviews Drug Discovery</i> , 2011, 10, 521-535.	21.5	1,038
120	Antitumor therapeutic effects of a genetically engineered <i>Salmonella typhimurium</i> harboring TNF- β in mice. <i>Applied Microbiology and Biotechnology</i> , 2011, 89, 1807-1819.	1.7	45
121	T cell augments the antitumor activity of tumor-targeting <i>Salmonella</i> . <i>Applied Microbiology and Biotechnology</i> , 2011, 90, 1381-1388.	1.7	61
122	Antibiotic control of tumor-colonizing <i>Salmonella enterica</i> serovar Typhimurium. <i>Experimental Biology and Medicine</i> , 2011, 236, 1282-1290.	1.1	9
123	Palmitoylation State Impacts Induction of Innate and Acquired Immunity by the <i>Salmonella enterica</i> Serovar Typhimurium Δ msbB Mutant. <i>Infection and Immunity</i> , 2011, 79, 5027-5038.	1.0	42
124	Proteomic Screening of Anaerobically Regulated Promoters from <i>Salmonella</i> and Its Antitumor Applications. <i>Molecular and Cellular Proteomics</i> , 2011, 10, M111.009399.	2.5	23
125	Research Spotlight: Delivery of therapeutic RNA molecules to cancer cells by bacteria. <i>Therapeutic Delivery</i> , 2011, 2, 441-449.	1.2	8
126	Oral Delivery of the Sj23LHD-GST Antigen by <i>Salmonella typhimurium</i> Type III Secretion System Protects against <i>Schistosoma japonicum</i> Infection in Mice. <i>PLoS Neglected Tropical Diseases</i> , 2011, 5, e1313.	1.3	23
127	Bugging Tumors. <i>Cancer Discovery</i> , 2012, 2, 588-590.	7.7	19
128	<i>Escherichia coli</i> Nissle 1917 Targets and Restrains Mouse B16 Melanoma and 4T1 Breast Tumors through Expression of Azurin Protein. <i>Applied and Environmental Microbiology</i> , 2012, 78, 7603-7610.	1.4	96

#	ARTICLE	IF	CITATIONS
129	A Bioluminescent Transposon Reporter-Trap Identifies Tumor-Specific Microenvironment-Induced Promoters in <i>Salmonella</i> for Conditional Bacterial-Based Tumor Therapy. <i>Cancer Discovery</i> , 2012, 2, 624-637.	7.7	58
130	Inhibition and eradication of human glioma with tumor-targeting <i>Salmonella typhimurium</i> in an orthotopic nude-mouse model. <i>Cell Cycle</i> , 2012, 11, 628-632.	1.3	80
131	The preclinical discovery of bacterial therapy for the treatment of metastatic cancer with unique advantages. <i>Expert Opinion on Drug Discovery</i> , 2012, 7, 73-83.	2.5	17
132	Explicit hypoxia targeting with tumor suppression by creating an obligate anaerobic <i>Salmonella Typhimurium</i> strain. <i>Scientific Reports</i> , 2012, 2, 436.	1.6	110
133	Identification of tumor-specific <i>Salmonella Typhimurium</i> promoters and their regulatory logic. <i>Nucleic Acids Research</i> , 2012, 40, 2984-2994.	6.5	49
135	<i>Salmonella enterica</i> serovars Typhimurium and Typhi as model organisms. <i>Virulence</i> , 2012, 3, 377-388.	1.8	65
136	Systemic Delivery of <i>Salmonella typhimurium</i> Transformed with IDO shRNA Enhances Intratumoral Vector Colonization and Suppresses Tumor Growth. <i>Cancer Research</i> , 2012, 72, 6447-6456.	0.4	84
137	Bringing next-generation therapeutics to the clinic through synthetic biology. <i>Current Opinion in Chemical Biology</i> , 2012, 16, 355-361.	2.8	17
138	Genetic Circuits in <i>Salmonella typhimurium</i> . <i>ACS Synthetic Biology</i> , 2012, 1, 458-464.	1.9	37
139	Effect of body shape on the motile behavior of bacteria-powered swimming microrobots (BacteriaBots). <i>Biomedical Microdevices</i> , 2012, 14, 999-1007.	1.4	51
141	Bacterial vectors for imaging and cancer gene therapy: a review. <i>Cancer Gene Therapy</i> , 2012, 19, 731-740.	2.2	50
142	Bioengineered microbes in disease therapy. <i>Trends in Molecular Medicine</i> , 2012, 18, 417-425.	3.5	44
143	High Resolution In Vivo Bioluminescent Imaging for the Study of Bacterial Tumour Targeting. <i>PLoS ONE</i> , 2012, 7, e30940.	1.1	116
144	<i>Salmonella enterica</i> as a vaccine carrier. <i>Future Microbiology</i> , 2012, 7, 111-127.	1.0	59
146	Motility is critical for effective distribution and accumulation of bacteria in tumor tissue. <i>Integrative Biology (United Kingdom)</i> , 2012, 4, 165-176.	0.6	108
148	Bacterial microsystems and microrobots. <i>Biomedical Microdevices</i> , 2012, 14, 1033-1045.	1.4	108
149	Effect of <i>Salmonella</i> treatment on an implanted tumor (CT26) in a mouse model. <i>Journal of Microbiology</i> , 2012, 50, 502-510.	1.3	13
150	Bacterial immunotherapy of gastrointestinal tumors. <i>Langenbeck's Archives of Surgery</i> , 2012, 397, 557-568.	0.8	26

#	ARTICLE	IF	CITATIONS
151	Polymer coatings for delivery of nucleic acid therapeutics. <i>Journal of Controlled Release</i> , 2012, 161, 537-553.	4.8	58
152	Engineering bacteria toward tumor targeting for cancer treatment: current state and perspectives. <i>Applied Microbiology and Biotechnology</i> , 2012, 93, 517-523.	1.7	61
153	A polymer coating applied to <i>Salmonella</i> prevents the binding of <i>Salmonella</i> -specific antibodies. <i>International Journal of Cancer</i> , 2013, 132, 717-725.	2.3	20
154	Bacteria and tumours: causative agents or opportunistic inhabitants?. <i>Infectious Agents and Cancer</i> , 2013, 8, 11.	1.2	129
155	Engineering of Bacteria for the Visualization of Targeted Delivery of a Cytolytic Anticancer Agent. <i>Molecular Therapy</i> , 2013, 21, 1985-1995.	3.7	94
156	Tumor-targeting <i>Salmonella typhimurium</i> , a natural tool for activation of prodrug 6MePdR and their combination therapy in murine melanoma model. <i>Applied Microbiology and Biotechnology</i> , 2013, 97, 4393-4401.	1.7	31
157	A therapeutic vaccine using <i>Salmonella</i> -modified tumor cells combined with interleukin-2 induces enhanced antitumor immunity in B-cell lymphoma. <i>Leukemia Research</i> , 2013, 37, 341-348.	0.4	17
158	The Evolution of Tumor-Targeted Drug Delivery: From the EPR Effect to Nanoswimmers. <i>Israel Journal of Chemistry</i> , 2013, 53, 719-727.	1.0	2
159	Cell and Molecular Biology of Breast Cancer. , 2013, , .		10
160	Expression of β -glucuronidase on the surface of bacteria enhances activation of glucuronide prodrugs. <i>Cancer Gene Therapy</i> , 2013, 20, 276-281.	2.2	14
161	<i>Salmonella Typhimurium</i> TTSS-2 deficient mig-14 mutant shows attenuation in immunocompromised mice and offers protection against wild-type <i>Salmonella Typhimurium</i> infection. <i>BMC Microbiology</i> , 2013, 13, 236.	1.3	9
162	Bacterial-directed enzyme prodrug therapy. <i>Journal of Controlled Release</i> , 2013, 170, 120-131.	4.8	61
163	Live-attenuated bacteria as a cancer vaccine vector. <i>Expert Review of Vaccines</i> , 2013, 12, 1139-1154.	2.0	74
164	MDR-selective microbial-based therapy: A novel approach to cancer treatment. <i>Medical Hypotheses</i> , 2013, 81, 207-211.	0.8	3
165	<i>Salmonella</i> SL7207 application is the most effective DNA vaccine delivery method for successful tumor eradication in a murine model for neuroblastoma. <i>Cancer Letters</i> , 2013, 331, 167-173.	3.2	53
166	New technologies in developing recombinant attenuated <i>Salmonella</i> vaccine vectors. <i>Microbial Pathogenesis</i> , 2013, 58, 17-28.	1.3	68
167	Cancer Immunotherapy. , 2013, , 198-214.		2
168	Measuring Growth and Gene Expression Dynamics of Tumor-Targeted <i>S. Typhimurium</i> Bacteria. <i>Journal of Visualized Experiments</i> , 2013, , e50540.	0.2	15

#	ARTICLE	IF	CITATIONS
169	Therapeutic Effects of Salmonella Typhi in a Mouse Model of T-Cell Lymphoma. Journal of Immunotherapy, 2013, 36, 171-180.	1.2	21
170	Tumor Growth Control with IDO-Silencing Salmonella. Reply. Cancer Research, 2013, 73, 4592-4593.	0.4	2
171	Deletion of the Braun Lipoprotein-Encoding Gene and Altering the Function of Lipopolysaccharide Attenuate the Plague Bacterium. Infection and Immunity, 2013, 81, 815-828.	1.0	27
172	Antigen-Specific Bacterial Vaccine Combined with Anti-PD-L1 Rescues Dysfunctional Endogenous T Cells to Reject Long-Established Cancer. Cancer Immunology Research, 2013, 1, 123-133.	1.6	61
173	Salmonella engineered to express CD20-targeting antibodies and a drug-converting enzyme can eradicate human lymphomas. Blood, 2013, 122, 705-714.	0.6	79
175	Melanoma vaccines: trials and tribulations. Vaccine (Auckland, N Z), 0, , 57.	1.7	12
176	Anti-Tumoral Effect of the Mitochondrial Target Domain of Noxa Delivered by an Engineered Salmonella typhimurium. PLoS ONE, 2014, 9, e80050.	1.1	71
177	Attenuated Listeria monocytogenes: a powerful and versatile vector for the future of tumor immunotherapy. Frontiers in Cellular and Infection Microbiology, 2014, 4, 51.	1.8	112
178	Pushing the Bacterial Envelope. , 2014, , 63-97.		1
179	Tumor-targeting <i>Salmonella typhimurium</i> A1-R decoys quiescent cancer cells to cycle as visualized by Fucci imaging and become sensitive to chemotherapy. Cell Cycle, 2014, 13, 3958-3963.	1.3	96
180	Salmonella as an Innovative Therapeutic Antitumor Agent. International Journal of Molecular Sciences, 2014, 15, 14546-14554.	1.8	46
181	Imaging for Infection: From Visualization of Inflammation to Visualization of Microbes. Surgical Infections, 2014, 15, 700-707.	0.7	31
182	Phenotypic Evolution of Therapeutic Salmonella enterica Serovar Typhimurium after Invasion of TRAMP Mouse Prostate Tumor. MBio, 2014, 5, e01182-14.	1.8	19
183	Efficacy of tumor-targeting <i>Salmonella typhimurium</i> A1-R on nude mouse models of metastatic and disseminated human ovarian cancer. Journal of Cellular Biochemistry, 2014, 115, n/a-n/a.	1.2	47
184	<i>Salmonella enterica</i> serovar <i>Typhimurium</i> immunotherapy for B-cell lymphoma induces broad anti-tumour immunity with therapeutic effect. Immunology, 2014, 143, 428-437.	2.0	53
185	Efficacy of <i>Salmonella typhimurium</i> A1-R Versus Chemotherapy on a Pancreatic Cancer Patient-Derived Orthotopic Xenograft (PDOX). Journal of Cellular Biochemistry, 2014, 115, 1254-1261.	1.2	93
186	A <i>Salmonella</i> Typhimurium mutant strain capable of RNAi delivery. Cancer Biology and Therapy, 2014, 15, 1068-1076.	1.5	23
187	CSPG4-Specific Immunity and Survival Prolongation in Dogs with Oral Malignant Melanoma Immunized with Human CSPG4 DNA. Clinical Cancer Research, 2014, 20, 3753-3762.	3.2	64

#	ARTICLE	IF	CITATIONS
188	Intratumoral injection of <i>Clostridium novyi</i> -NT spores induces antitumor responses. <i>Science Translational Medicine</i> , 2014, 6, 249ra111.	5.8	285
189	Tumor-colonizing bacteria: A potential tumor targeting therapy. <i>Critical Reviews in Microbiology</i> , 2014, 40, 225-235.	2.7	34
190	Genetically Engineered <i>Salmonella typhimurium</i> for Targeted Cancer Therapy. , 2014, , 443-452.		2
191	Bacterial Delivery of RNAi Effectors. , 2014, , 67-75.		1
192	Complete genome sequence of <i>Salmonella enterica</i> serovar Typhimurium VNP20009, a strain engineered for tumor targeting. <i>Journal of Biotechnology</i> , 2014, 192, 177-178.	1.9	22
194	Apoptins: selective anticancer agents. <i>Trends in Molecular Medicine</i> , 2014, 20, 519-528.	3.5	35
195	Methods for the development of tumor-targeting bacteria. <i>Expert Opinion on Drug Discovery</i> , 2014, 9, 741-750.	2.5	40
196	<i>Salmonella</i> as a biological "Trojan horse" for neoplasia: Future possibilities including brain cancer. <i>Medical Hypotheses</i> , 2014, 83, 343-345.	0.8	3
197	Lipid A controls the robustness of intratumoral accumulation of attenuated <i>Salmonella</i> in mice. <i>International Journal of Cancer</i> , 2014, 135, 647-657.	2.3	18
198	Neoadjuvant administration of Semliki Forest virus expressing interleukin-12 combined with attenuated <i>Salmonella</i> eradicates breast cancer metastasis and achieves long-term survival in immunocompetent mice. <i>BMC Cancer</i> , 2015, 15, 620.	1.1	30
199	Persistent enhancement of bacterial motility increases tumor penetration. <i>Biotechnology and Bioengineering</i> , 2015, 112, 2397-2405.	1.7	24
200	Treating cancer with infection: a review on bacterial cancer therapy. <i>Letters in Applied Microbiology</i> , 2015, 61, 107-112.	1.0	13
201	Induction of $CD4^{+}$ and $CD8^{+}$ anti-tumor effector T cell responses by bacteria mediated tumor therapy. <i>International Journal of Cancer</i> , 2015, 137, 2019-2028.	2.3	72
202	Combined bacterial and viral treatment: a novel anticancer strategy. <i>Central-European Journal of Immunology</i> , 2015, 3, 366-372.	0.4	6
203	The engineered <i>Salmonella typhimurium</i> inhibits tumorigenesis in advanced glioma. <i>OncoTargets and Therapy</i> , 2015, 8, 2555.	1.0	6
204	Vasculature Disruption Enhances Bacterial Targeting of Autochthonous Tumors. <i>Journal of Cancer</i> , 2015, 6, 843-848.	1.2	15
205	Synthetic biology expands chemical control of microorganisms. <i>Current Opinion in Chemical Biology</i> , 2015, 28, 20-28.	2.8	27
206	Programmable probiotics for detection of cancer in urine. <i>Science Translational Medicine</i> , 2015, 7, 289ra84.	5.8	326

#	ARTICLE	IF	CITATIONS
208	Trg-deficient Salmonella colonize quiescent tumor regions by exclusively penetrating or proliferating. Journal of Controlled Release, 2015, 199, 180-189.	4.8	27
209	Rescuing chemotaxis of the anticancer agent Salmonella enterica serovar Typhimurium VNP20009. Journal of Biotechnology, 2015, 211, 117-120.	1.9	17
210	Tissue penetration of bacteria into quiescent regions of tumors. Journal of Controlled Release, 2015, 199, 198.	4.8	0
211	Genetically modified bacteria as a tool to detect microscopic solid tumor masses with triggered release of a recombinant biomarker. Integrative Biology (United Kingdom), 2015, 7, 423-434.	0.6	36
212	Immunopathology and Immunotherapy of Non-Hodgkin Lymphoma. , 2015, , 135-183.		0
213	<i>Salmonella</i>-Based Therapy Targeting Indoleamine 2,3-Dioxygenase Coupled with Enzymatic Depletion of Tumor Hyaluronan Induces Complete Regression of Aggressive Pancreatic Tumors. Cancer Immunology Research, 2015, 3, 1096-1107.	1.6	58
214	Engineered bacteria as therapeutic agents. Current Opinion in Biotechnology, 2015, 35, 94-102.	3.3	83
215	Efficiency of Conditionally Attenuated Salmonella enterica Serovar Typhimurium in Bacterium-Mediated Tumor Therapy. MBio, 2015, 6, .	1.8	68
216	Potent and tumor specific: arming bacteria with therapeutic proteins. Therapeutic Delivery, 2015, 6, 385-399.	1.2	40
217	Engineering Nanoparticle-Coated Bacteria as Oral DNA Vaccines for Cancer Immunotherapy. Nano Letters, 2015, 15, 2732-2739.	4.5	213
218	Back to the Future: Are Tumor-Targeting Bacteria the Next-Generation Cancer Therapy?. Methods in Molecular Biology, 2015, 1317, 239-260.	0.4	18
219	Development of Salmonella-Based Cancer Vaccines. , 2015, , 377-386.		0
220	Direct Attachment of Nanoparticle Cargo to Salmonella typhimurium Membranes Designed for Combination Bacteriotherapy Against Tumors. Methods in Molecular Biology, 2015, 1225, 151-163.	0.4	16
221	Salmonella. Methods in Molecular Biology, 2015, , .	0.4	5
222	Programming Controlled Adhesion of <i>E. coli</i> to Target Surfaces, Cells, and Tumors with Synthetic Adhesins. ACS Synthetic Biology, 2015, 4, 463-473.	1.9	133
223	<i>Salmonella</i>overcomes tumor immune tolerance by inhibition of tumor indoleamine 2, 3-dioxygenase 1 expression. Oncotarget, 2016, 7, 374-385.	0.8	37
224	Strains, Mechanism, and Perspective:<i>Salmonella</i>-Based Cancer Therapy. International Journal of Microbiology, 2016, 2016, 1-10.	0.9	47
225	Bacteria in Cancer Therapy: Renaissance of an Old Concept. International Journal of Microbiology, 2016, 2016, 1-14.	0.9	117

#	ARTICLE	IF	CITATIONS
226	Therapy of solid tumors using probiotic Symbioflor-2 - restraints and potential. <i>Oncotarget</i> , 2016, 7, 22605-22622.	0.8	35
227	Immunotherapy for human papillomavirus-associated disease and cervical cancer: review of clinical and translational research. <i>Journal of Gynecologic Oncology</i> , 2016, 27, e51.	1.0	99
228	Targeted Cancer Therapy Using Engineered <i>Salmonella typhimurium</i> . <i>Chonnam Medical Journal</i> , 2016, 52, 173.	0.5	59
229	Efficacy of Tumor-Targeting <i>Salmonella</i> A1-R on a Melanoma Patient-Derived Orthotopic Xenograft (PDOX) Nude-Mouse Model. <i>PLoS ONE</i> , 2016, 11, e0160882.	1.1	93
230	<i>Salmonella</i> Bacterial Monotherapy Reduces Autochthonous Prostate Tumor Burden in the TRAMP Mouse Model. <i>PLoS ONE</i> , 2016, 11, e0160926.	1.1	9
231	RGD Peptide Cell-Surface Display Enhances the Targeting and Therapeutic Efficacy of Attenuated <i>Salmonella</i> -mediated Cancer Therapy. <i>Theranostics</i> , 2016, 6, 1672-1682.	4.6	107
232	EGFR-targeted Chimeras of <i>Pseudomonas</i> ToxA released into the extracellular milieu by attenuated <i>Salmonella</i> selectively kill tumor cells. <i>Biotechnology and Bioengineering</i> , 2016, 113, 2698-2711.	1.7	16
233	Chloroquine enhanced the anticancer capacity of VNP20009 by inhibiting autophagy. <i>Scientific Reports</i> , 2016, 6, 29774.	1.6	10
234	Suppression of pancreatic ductal adenocarcinoma growth by intratumoral delivery of attenuated <i>Salmonella typhimurium</i> using a dual fluorescent live tracking system. <i>Cancer Biology and Therapy</i> , 2016, 17, 732-740.	1.5	22
235	A phase I clinical study to evaluate safety of orally administered, genetically engineered <i>Salmonella enterica</i> serovar <i>Typhimurium</i> for canine osteosarcoma. <i>Veterinary Medicine and Science</i> , 2016, 2, 179-190.	0.6	42
236	Biomimetic <i>Salmonella</i> : A Next-Generation Therapeutic Vector?. <i>Trends in Microbiology</i> , 2016, 24, 850-852.	3.5	16
237	Anaerobes in Biotechnology. <i>Advances in Biochemical Engineering/Biotechnology</i> , 2016, , .	0.6	9
238	Anaerobes as Sources of Bioactive Compounds and Health Promoting Tools. <i>Advances in Biochemical Engineering/Biotechnology</i> , 2016, 156, 433-464.	0.6	12
239	A <i>Salmonella</i> nanoparticle mimic overcomes multidrug resistance in tumours. <i>Nature Communications</i> , 2016, 7, 12225.	5.8	62
240	Antimelanoma effect of <i>Salmonella</i> Typhimurium integration host factor mutant in murine model. <i>Future Oncology</i> , 2016, 12, 2367-2378.	1.1	2
242	Diagnosis of cancer multidrug resistance by bacterium-mediated imaging. <i>Medical Hypotheses</i> , 2016, 89, 11-15.	0.8	1
243	Biobots. <i>Microbes and Infection</i> , 2016, 18, 373-377.	1.0	3
244	Improving cancer therapies by targeting the physical and chemical hallmarks of the tumor microenvironment. <i>Cancer Letters</i> , 2016, 380, 330-339.	3.2	56

#	ARTICLE	IF	CITATIONS
245	Bacteria and genetically modified bacteria as cancer therapeutics: Current advances and challenges. <i>Cytokine</i> , 2017, 89, 160-172.	1.4	60
246	Bacterial Carriers for Glioblastoma Therapy. <i>Molecular Therapy - Oncolytics</i> , 2017, 4, 1-17.	2.0	26
247	Carcinogenesis and therapeutics: the microbiota perspective. <i>Nature Microbiology</i> , 2017, 2, 17008.	5.9	108
248	Two-step enhanced cancer immunotherapy with engineered <i>Salmonella typhimurium</i> secreting heterologous flagellin. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	373
249	Optimizing the restored chemotactic behavior of anticancer agent <i>Salmonella enterica</i> serovar Typhimurium VNP20009. <i>Journal of Biotechnology</i> , 2017, 251, 76-83.	1.9	20
250	Utilizing <i>Salmonella</i> to treat solid malignancies. <i>Journal of Surgical Oncology</i> , 2017, 116, 75-82.	0.8	7
251	Intracellular delivery of biologic therapeutics by bacterial secretion systems. <i>Expert Reviews in Molecular Medicine</i> , 2017, 19, e6.	1.6	22
252	Anticancer effects of the microbiome and its products. <i>Nature Reviews Microbiology</i> , 2017, 15, 465-478.	13.6	399
253	<i>Salmonella typhimurium</i> A1-R targeting of a chemotherapy-resistant BRAF-V600E melanoma in a patient-derived orthotopic xenograft (PDOX) model is enhanced in combination with either vemurafenib or temozolomide. <i>Cell Cycle</i> , 2017, 16, 1288-1294.	1.3	37
254	Advances in bacterial cancer therapies using synthetic biology. <i>Current Opinion in Systems Biology</i> , 2017, 5, 1-8.	1.3	68
255	The Boosting Potential of Bacteria in Cancer Immunotherapy. <i>Trends in Molecular Medicine</i> , 2017, 23, 580-582.	3.5	10
256	Can a nanoparticle that mimics <i>Salmonella</i> effectively combat tumor chemotherapy resistance?. <i>Nanomedicine</i> , 2017, 12, 705-710.	1.7	2
257	Tumour-targeting bacteria-based cancer therapies for increased specificity and improved outcome. <i>Microbial Biotechnology</i> , 2017, 10, 1074-1078.	2.0	33
258	Autonomous bacterial nanoswimmers target cancer. <i>Journal of Controlled Release</i> , 2017, 257, 68-75.	4.8	39
259	Application of genetically engineered <i>Salmonella typhimurium</i> for interferon-gamma-induced therapy against melanoma. <i>European Journal of Cancer</i> , 2017, 70, 48-61.	1.3	74
260	Modulation of <i>Salmonella</i> Tumor-Colonization and Intratumoral Anti-angiogenesis by Triptolide and Its Mechanism. <i>Theranostics</i> , 2017, 7, 2250-2260.	4.6	56
261	<i>Proteus mirabilis</i> inhibits cancer growth and pulmonary metastasis in a mouse breast cancer model. <i>PLoS ONE</i> , 2017, 12, e0188960.	1.1	16
262	The inhibition of indoleamine 2, 3-dioxygenase 1 by connexin 43. <i>International Journal of Medical Sciences</i> , 2017, 14, 1181-1188.	1.1	24

#	ARTICLE	IF	CITATIONS
263	Anti-tumor activity of an immunotoxin (TGF β -PE38) delivered by attenuated <i>Salmonella typhimurium</i> . <i>Oncotarget</i> , 2017, 8, 37550-37560.	0.8	53
264	The concept of immune surveillance against tumors: The first theories. <i>Oncotarget</i> , 2017, 8, 7175-7180.	0.8	221
265	Therapeutic benefit of <i>Salmonella</i> attributed to LPS and TNF- β is exhaustible and dictated by tumor susceptibility. <i>Oncotarget</i> , 2017, 8, 36492-36508.	0.8	32
266	Bacterial type III secretion system as a protein delivery tool for a broad range of biomedical applications. <i>Biotechnology Advances</i> , 2018, 36, 482-493.	6.0	40
267	Engineering bacteria for diagnostic and therapeutic applications. <i>Nature Reviews Microbiology</i> , 2018, 16, 214-225.	13.6	267
268	Conditional constitutive expression system of a drug protein <i>in vivo</i> by positive feedback loop using an inducer-independent artificial transcription factor. <i>Biochemical and Biophysical Research Communications</i> , 2018, 495, 2390-2395.	1.0	1
269	Potential usefulness of <i>Brevibacillus</i> for bacterial cancer therapy: intratumoral provision of tumor necrosis factor- β and anticancer effects. <i>Cancer Gene Therapy</i> , 2018, 25, 47-57.	2.2	3
270	Bacterial ghosts as adjuvant to oxaliplatin chemotherapy in colorectal carcinomatosis. <i>Oncolmmunology</i> , 2018, 7, e1424676.	2.1	35
271	Peyer's Patches as a Portal for DNA Delivery by <i>Lactococcus lactis</i> <i>in vivo</i> . <i>Biological and Pharmaceutical Bulletin</i> , 2018, 41, 190-197.	0.6	5
272	Attenuated <i>Salmonella</i> VNP20009 mutant (<i>htrA</i>) is a promising candidate for bacteria-mediated tumour therapy in hosts with TNFR1 deficiency. <i>Letters in Applied Microbiology</i> , 2018, 67, 97-103.	1.0	10
273	Engineered <i>Salmonella enterica</i> serovar Typhimurium overcomes limitations of anti-bacterial immunity in bacteria-mediated tumor therapy. <i>Oncolmmunology</i> , 2018, 7, e1382791.	2.1	46
274	Comparison of the common bacteria in human and mouse tumours using high-throughput sequencing. <i>Molecular Medicine Reports</i> , 2018, 17, 6717-6722.	1.1	3
275	<i>Salmonella</i> and Biotechnology. , 0, , .		0
276	Tumour-targeting bacteria engineered to fight cancer. <i>Nature Reviews Cancer</i> , 2018, 18, 727-743.	12.8	439
277	Cancer Immunotherapy: Priming the Host Immune Response with Live Attenuated <i>Salmonella enterica</i> . <i>Journal of Immunology Research</i> , 2018, 2018, 1-15.	0.9	30
278	Technetium-99m-based simple and convenient radiolabeling of <i>Escherichia coli</i> for <i>in vivo</i> tracking of microorganisms. <i>Journal of Radioanalytical and Nuclear Chemistry</i> , 2018, 317, 997-1003.	0.7	4
279	Infection by <i>Salmonella enterica</i> ; Promotes or Demotes Tumor Development. , 0, , .		1
280	Computational Models for Trapping Ebola Virus Using Engineered Bacteria. <i>IEEE/ACM Transactions on Computational Biology and Bioinformatics</i> , 2018, 15, 2017-2027.	1.9	8

#	ARTICLE	IF	CITATIONS
281	Bacteria-Driven Hypoxia Targeting for Combined Biotherapy and Photothermal Therapy. ACS Nano, 2018, 12, 5995-6005.	7.3	253
282	Endostatin gene therapy delivered by attenuated <i>Salmonella typhimurium</i> in murine tumor models. Cancer Gene Therapy, 2018, 25, 167-183.	2.2	33
283	Construction of Bacteria-Based Cargo Carriers for Targeted Cancer Therapy. Methods in Molecular Biology, 2018, 1831, 25-35.	0.4	4
284	Bacterial Therapy of Cancer: Promises, Limitations, and Insights for Future Directions. Frontiers in Microbiology, 2018, 9, 16.	1.5	98
285	Potentiating bacterial cancer therapy using hydroxychloroquine liposomes. Journal of Controlled Release, 2018, 280, 39-50.	4.8	22
286	White paper on microbial anti-cancer therapy and prevention. , 2018, 6, 78.		108
287	Part I: fighting cancer with deadly bacteria. BioTechniques, 2018, 64, 6-8.	0.8	3
288	Camouflaging bacteria by wrapping with cell membranes. Nature Communications, 2019, 10, 3452.	5.8	149
289	Bacterial Targeting of Tumors. , 2019, , .		0
290	Oncolytic Bacteria and their potential role in bacterium-mediated tumour therapy: a conceptual analysis. Journal of Cancer, 2019, 10, 4442-4454.	1.2	21
291	<i>Salmonella</i> -Mediated Cancer Therapy: An Innovative Therapeutic Strategy. Journal of Cancer, 2019, 10, 4765-4776.	1.2	45
292	Efficacy of Tumor-Targeting <i>Salmonella typhimurium</i> A1-R against Malignancies in Patient-Derived Orthotopic Xenograft (PDOX) Murine Models. Cells, 2019, 8, 599.	1.8	18
293	Application of Bacterial Whole-Cell Biosensors in Health. , 2019, , 1-17.		1
294	Oncolytic bacteria: past, present and future. FEMS Microbiology Letters, 2019, 366, .	0.7	15
295	Bacteria in Cancer Therapeutics: A Framework for Effective Therapeutic Bacterial Screening and Identification. Journal of Cancer, 2019, 10, 1781-1793.	1.2	15
296	Vaccination against <i>Clostridium difficile</i> by Use of an Attenuated <i>Salmonella enterica</i> Serovar Typhimurium Vector (YS1646) Protects Mice from Lethal Challenge. Infection and Immunity, 2019, 87, .	1.0	6
297	Salmonella-Based Targeted Cancer Therapy: Updates on A Promising and Innovative Tumor Immunotherapeutic Strategy. Biomedicines, 2019, 7, 36.	1.4	26
298	Rapid screening of engineered microbial therapies in a 3D multicellular model. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 9002-9007.	3.3	30

#	ARTICLE	IF	CITATIONS
299	Therapeutic bacteria to combat cancer; current advances, challenges, and opportunities. <i>Cancer Medicine</i> , 2019, 8, 3167-3181.	1.3	191
300	Perfluorocarbon regulates the intratumoural environment to enhance hypoxia-based agent efficacy. <i>Nature Communications</i> , 2019, 10, 1580.	5.8	85
301	Genetically engineered <i>Salmonella</i> Typhimurium: Recent advances in cancer therapy. <i>Cancer Letters</i> , 2019, 448, 168-181.	3.2	80
302	The motility regulator flhDC drives intracellular accumulation and tumor colonization of <i>Salmonella</i> . , 2019, 7, 44.		16
303	Overcoming the challenges of cancer drug resistance through bacterial-mediated therapy. <i>Chronic Diseases and Translational Medicine</i> , 2019, 5, 258-266.	0.9	18
304	Canine Cancer: Strategies in Experimental Therapeutics. <i>Frontiers in Oncology</i> , 2019, 9, 1257.	1.3	26
305	Cancer Immunotherapy. , 2019, , 231-250.		0
306	<i>Salmonella</i> Typhimurium as an Anticancer Therapy: Recent Advances and Perspectives. <i>Current Clinical Microbiology Reports</i> , 2019, 6, 225-239.	1.8	17
307	Vaccination against the digestive enzyme Cathepsin B using a YS1646 <i>Salmonella enterica</i> Typhimurium vector provides almost complete protection against <i>Schistosoma mansoni</i> challenge in a mouse model. <i>PLoS Neglected Tropical Diseases</i> , 2019, 13, e0007490.	1.3	15
308	Bacteria-cancer interactions: bacteria-based cancer therapy. <i>Experimental and Molecular Medicine</i> , 2019, 51, 1-15.	3.2	233
309	Triptolide modulates tumour-colonisation and anti-tumour effect of attenuated <i>Salmonella</i> encoding DNase I. <i>Applied Microbiology and Biotechnology</i> , 2019, 103, 929-939.	1.7	22
310	Gut Microbiota and Cancer: From Pathogenesis to Therapy. <i>Cancers</i> , 2019, 11, 38.	1.7	378
311	Nanoscale Bacteria-enabled Autonomous Drug Delivery System (NanoBEADS) Enhances Intratumoral Transport of Nanomedicine. <i>Advanced Science</i> , 2019, 6, 1801309.	5.6	104
312	Detection of tumors with fluoromarker-releasing bacteria. <i>International Journal of Cancer</i> , 2020, 146, 137-149.	2.3	12
313	Nontyphoidal <i>Salmonella</i> : a potential anticancer agent. <i>Journal of Applied Microbiology</i> , 2020, 128, 2-14.	1.4	11
314	<i>Salmonella</i> -mediated therapy targeting indoleamine 2, 3-dioxygenase 1 (IDO) activates innate immunity and mitigates colorectal cancer growth. <i>Cancer Gene Therapy</i> , 2020, 27, 235-245.	2.2	42
315	Targeted cancer immunotherapy with genetically engineered oncolytic <i>Salmonella typhimurium</i> . <i>Cancer Letters</i> , 2020, 469, 102-110.	3.2	67
316	The First Clinical Use of a Recombinant <i>Lactococcus lactis</i> Expressing Human Papillomavirus Type 16 E7 Oncogene Oral Vaccine: A Phase I Safety and Immunogenicity Trial in Healthy Women Volunteers. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 717-727.	1.9	24

#	ARTICLE	IF	CITATIONS
317	Bioengineering Bacterial Vesicle-Coated Polymeric Nanomedicine for Enhanced Cancer Immunotherapy and Metastasis Prevention. <i>Nano Letters</i> , 2020, 20, 11-21.	4.5	175
318	Emerging therapeutic approaches for canine sarcomas: Pushing the boundaries beyond the conventional. <i>Veterinary and Comparative Oncology</i> , 2020, 18, 9-24.	0.8	7
319	Bioengineered <i>Escherichia coli</i> Nissle 1917 for tumour-targeting therapy. <i>Microbial Biotechnology</i> , 2020, 13, 629-636.	2.0	67
320	Salmonella Breaks Tumor Immune Tolerance by Downregulating Tumor Programmed Death-Ligand 1 Expression. <i>Cancers</i> , 2020, 12, 57.	1.7	22
321	Obligate and facultative anaerobic bacteria in targeted cancer therapy: Current strategies and clinical applications. <i>Life Sciences</i> , 2020, 261, 118296.	2.0	40
322	Microbes as Medicines: Harnessing the Power of Bacteria in Advancing Cancer Treatment. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7575.	1.8	44
323	Entirely Synthetic Bacterial Nanomimics for Highly-Effective Tumor Suppression and Immune Elicitation. <i>Nano Today</i> , 2020, 35, 100950.	6.2	9
324	Microbes as Biosensors. <i>Annual Review of Microbiology</i> , 2020, 74, 337-359.	2.9	35
325	Engineering Living Bacteria for Cancer Therapy. <i>ACS Applied Bio Materials</i> , 2020, 3, 8136-8145.	2.3	18
326	Attenuated <i>Salmonella enterica</i> Serovar Typhimurium, Strain NC983, Is Immunogenic, and Protective against Virulent Typhimurium Challenges in Mice. <i>Vaccines</i> , 2020, 8, 646.	2.1	2
327	Engineering the gut microbiota to treat chronic diseases. <i>Applied Microbiology and Biotechnology</i> , 2020, 104, 7657-7671.	1.7	19
328	Tumor Subtype Determines Therapeutic Response to Chimeric Polypeptide Nanoparticle-based Chemotherapy in <i>Pten</i> -deleted Mouse Models of Sarcoma. <i>Clinical Cancer Research</i> , 2020, 26, 5036-5047.	3.2	6
329	Bacteria-triggered tumor-specific thrombosis to enable potent photothermal immunotherapy of cancer. <i>Science Advances</i> , 2020, 6, eaba3546.	4.7	144
330	A Phase I, Dose Escalation, Single Dose Trial of Oral Attenuated <i>Salmonella typhimurium</i> Containing Human IL-2 in Patients With Metastatic Gastrointestinal Cancers. <i>Journal of Immunotherapy</i> , 2020, 43, 217-221.	1.2	27
331	Inhibition of acute leukemia with attenuated <i>Salmonella typhimurium</i> strain VNP20009. <i>Biomedicine and Pharmacotherapy</i> , 2020, 129, 110425.	2.5	10
332	Development of Dual-Scale Fluorescence Endoscopy for In Vivo Bacteria Imaging in an Orthotopic Mouse Colon Tumor Model. <i>Applied Sciences (Switzerland)</i> , 2020, 10, 844.	1.3	4
333	Engineering probiotics as living diagnostics and therapeutics for improving human health. <i>Microbial Cell Factories</i> , 2020, 19, 56.	1.9	71
334	Bacteria and cancer: Different sides of the same coin. <i>Life Sciences</i> , 2020, 246, 117398.	2.0	38

#	ARTICLE	IF	CITATIONS
335	Paclitaxel-in-liposome-in-bacteria for inhalation treatment of primary lung cancer. <i>International Journal of Pharmaceutics</i> , 2020, 578, 119177.	2.6	48
336	Data-driven statistical modeling of the emergent behavior of biohybrid microrobots. <i>APL Bioengineering</i> , 2020, 4, 016104.	3.3	5
337	Bioengineered smart bacterial carriers for combinational targeted therapy of solid tumours. <i>Journal of Drug Targeting</i> , 2020, 28, 700-713.	2.1	24
338	Hyaluronidase-Expressing <i>Salmonella</i> Effectively Targets Tumor-Associated Hyaluronic Acid in Pancreatic Ductal Adenocarcinoma. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 706-716.	1.9	26
339	Imaging of tumor colonization by <i>Escherichia coli</i> using ¹⁸ F-FDS PET. <i>Theranostics</i> , 2020, 10, 4958-4966.	4.6	40
340	Gut microbiota contributes towards immunomodulation against cancer: New frontiers in precision cancer therapeutics. <i>Seminars in Cancer Biology</i> , 2021, 70, 11-23.	4.3	26
341	Twenty years of research on HPV vaccines based on genetically modified lactic acid bacteria: an overview on the gut-vagina axis. <i>Cellular and Molecular Life Sciences</i> , 2021, 78, 1191-1206.	2.4	27
342	New technologies in developing recombinant-attenuated bacteria for cancer therapy. <i>Biotechnology and Bioengineering</i> , 2021, 118, 513-530.	1.7	17
343	Tweak to Treat: Reprogramming Bacteria for Cancer Treatment. <i>Trends in Cancer</i> , 2021, 7, 447-464.	3.8	71
344	Ampullary Adenocarcinoma: a Mini-Review and a Case Report of a Clinically Stable Disease Patient Treated with Herbal Supplements. <i>Journal of Gastrointestinal Cancer</i> , 2021, 52, 750-758.	0.6	1
345	Perspectives on Oncolytic Salmonella in Cancer Immunotherapy—A Promising Strategy. <i>Frontiers in Immunology</i> , 2021, 12, 615930.	2.2	12
346	Acquired Fanconi Syndrome in a Patient with Nontyphoidal <i>Salmonella</i> ; Bacteremia. <i>Internal Medicine</i> , 2021, 60, 761-764.	0.3	1
347	Phenotypic characterization of auxotrophic mutant of nontyphoidal <i>Salmonella</i> and determination of its cytotoxicity, tumor inhibiting cytokine gene expression in cell line models. <i>Archives of Microbiology</i> , 2021, 203, 2925-2939.	1.0	0
348	The next frontier of oncotherapy: accomplishing clinical translation of oncolytic bacteria through genetic engineering. <i>Future Microbiology</i> , 2021, 16, 341-368.	1.0	5
349	IFN- γ -dependent NK cell activation is essential to metastasis suppression by engineered <i>Salmonella</i> . <i>Nature Communications</i> , 2021, 12, 2537.	5.8	36
350	Theranostic cells: emerging clinical applications of synthetic biology. <i>Nature Reviews Genetics</i> , 2021, 22, 730-746.	7.7	49
352	Tumor Temporal Proteome Profiling Reveals the Immunological Triple Offensive Induced by Synthetic Anti-Cancer <i>Salmonella</i> . <i>Frontiers in Immunology</i> , 2021, 12, 712936.	2.2	6
353	Synergistic effects of arsenic trioxide combined with <i>Salmonella typhimurium</i> in treating the advanced hepatocellular carcinoma in rat models. <i>Journal of Gastrointestinal Oncology</i> , 2021, 12, 1732-1742.	0.6	3

#	ARTICLE	IF	CITATIONS
354	Isolation and Analysis of Suppressor Mutations in Tumor-Targeted msbB Salmonella. <i>Methods in Molecular Biology</i> , 2016, 1409, 95-123.	0.4	3
355	Tumor-Targeting Therapy Using Gene-Engineered Anaerobic-Nonpathogenic <i>Bifidobacterium longum</i> . <i>Methods in Molecular Biology</i> , 2016, 1409, 49-60.	0.4	25
356	Tumor-Targeted <i>Salmonella typhimurium</i> Overexpressing Cytosine Deaminase: A Novel, Tumor-Selective Therapy. <i>Methods in Molecular Biology</i> , 2009, 542, 649-659.	0.4	23
357	Development of Bacterial Vectors for Tumor-Targeted Gene Therapy. <i>Methods in Molecular Biology</i> , 2009, 542, 131-154.	0.4	7
358	Employing Live Microbes for Vaccine Delivery. , 2012, , 87-124.		4
359	Current Status and Biomedical Applications of Ribosome-Inactivating Proteins. , 2013, , 145-179.		5
361	Inflammation drives thrombosis after <i>Salmonella</i> infection via CLEC-2 on platelets. <i>Journal of Clinical Investigation</i> , 2015, 125, 4429-4446.	3.9	135
362	Bacterial delivery of the anti-tumor azurin-like protein Laz to glioblastoma cells. <i>AMB Express</i> , 2020, 10, 59.	1.4	8
363	Tumor Invasion of <i>Salmonella enterica</i> Serovar Typhimurium Is Accompanied by Strong Hemorrhage Promoted by TNF- α . <i>PLoS ONE</i> , 2009, 4, e6692.	1.1	174
364	Live Attenuated <i>S. Typhimurium</i> Vaccine with Improved Safety in Immuno-Compromised Mice. <i>PLoS ONE</i> , 2012, 7, e45433.	1.1	25
365	Composing a Tumor Specific Bacterial Promoter. <i>PLoS ONE</i> , 2016, 11, e0155338.	1.1	9
366	Antitumour activity of <i>Salmonella typhimurium</i> VNP20047 in B16(F10) murine melanoma model.. <i>Acta Biochimica Polonica</i> , 2004, 51, 851-856.	0.3	10
367	<i>Salmonella</i> and cancer: from pathogens to therapeutics.. <i>Acta Biochimica Polonica</i> , 2013, 60, .	0.3	51
368	Targeting tumors with salmonella Typhimurium- potential for therapy. <i>Oncotarget</i> , 2010, 1, 721-8.	0.8	29
369	The genes <i>slyA</i> , <i>STM3120</i> and <i>htrA</i> are required for the anticancer ability of VNP20009. <i>Oncotarget</i> , 2016, 7, 81187-81196.	0.8	8
370	32-Phosphorus selectively delivered by listeria to pancreatic cancer demonstrates a strong therapeutic effect. <i>Oncotarget</i> , 2017, 8, 20729-20740.	0.8	38
371	Effect of <i>Salmonella enterica</i> serovar Typhimurium VNP20009 and VNP20009 with restored chemotaxis on 4T1 mouse mammary carcinoma progression. <i>Oncotarget</i> , 2017, 8, 33601-33613.	0.8	21
372	Toxicology and efficacy of tumor-targeting <i>Salmonella typhimurium</i> A1-R compared to VNP 20009 in a syngeneic mouse tumor model in immunocompetent mice. <i>Oncotarget</i> , 2017, 8, 54616-54628.	0.8	16

#	ARTICLE	IF	CITATIONS
373	Local application of bacteria improves safety of <i>Salmonella</i> -mediated tumor therapy and retains advantages of systemic infection. <i>Oncotarget</i> , 2017, 8, 49988-50001.	0.8	27
374	Cell mass-dependent expression of an anticancer protein drug by tumor-targeted <i>Salmonella</i> . <i>Oncotarget</i> , 2018, 9, 8548-8559.	0.8	13
375	Tumor-targeting <i>Salmonella typhimurium</i> A1-R arrests growth of breast-cancer brain metastasis. <i>Oncotarget</i> , 2015, 6, 2615-2622.	0.8	59
376	Comparison of the selective targeting efficacy of <i>Salmonella typhimurium</i> A1-R and VNP20009 on the Lewis lung carcinoma in nude mice. <i>Oncotarget</i> , 2015, 6, 14625-14631.	0.8	33
377	Intraperitoneal administration of tumor-targeting <i>Salmonella typhimurium</i> A1-R inhibits disseminated human ovarian cancer and extends survival in nude mice. <i>Oncotarget</i> , 2015, 6, 11369-11377.	0.8	55
378	Therapeutic efficacy of tumor-targeting <i>Salmonella typhimurium</i> A1-R on human colorectal cancer liver metastasis in orthotopic nude-mouse models. <i>Oncotarget</i> , 2015, 6, 31368-31377.	0.8	14
379	Adjuvant treatment with tumor-targeting <i>Salmonella typhimurium</i> A1-R reduces recurrence and increases survival after liver metastasis resection in an orthotopic nude mouse model. <i>Oncotarget</i> , 2015, 6, 41856-41862.	0.8	13
380	Tumor-targeting <i>Salmonella typhimurium</i> A1-R in combination with doxorubicin eradicate soft tissue sarcoma in a patient-derived orthotopic xenograft (PDOX) model. <i>Oncotarget</i> , 2016, 7, 12783-12790.	0.8	109
381	Blockage of autophagy pathway enhances <i>Salmonella</i> tumor-targeting. <i>Oncotarget</i> , 2016, 7, 22873-22882.	0.8	24
382	High efficacy of tumor-targeting <i>Salmonella typhimurium</i> A1-R on a doxorubicin- and dactolisib-resistant follicular dendritic-cell sarcoma in a patient-derived orthotopic xenograft PDOX nude mouse model. <i>Oncotarget</i> , 2016, 7, 33046-33054.	0.8	93
383	Solid tumors provide niche-specific conditions that lead to preferential growth of <i>Salmonella</i> . <i>Oncotarget</i> , 2016, 7, 35169-35180.	0.8	35
384	Hypoxia Responsive Drug Delivery Systems in Tumor Therapy. <i>Current Pharmaceutical Design</i> , 2016, 22, 2808-2820.	0.9	34
385	AAVs Anatomy: Roadmap for Optimizing Vectors for Translational Success. <i>Current Gene Therapy</i> , 2010, 10, 319-340.	0.9	85
386	Local Gene Delivery for Cancer Therapy. <i>Current Gene Therapy</i> , 2011, 11, 423-432.	0.9	20
387	Tumor-Specific Delivery of Histidine-Rich Glycoprotein Suppresses Tumor Growth and Metastasis by Anti-angiogenesis and Vessel Normalization. <i>Current Gene Therapy</i> , 2014, 14, 75-85.	0.9	14
388	Genetically Modified Bacteria as Targeted Agent for Cancer. <i>The Korean Journal of Urological Oncology</i> , 2016, 14, 54-62.	0.1	1
389	Live, Attenuated <i>Salmonella</i> Vaccine Vectors. , 2003, , 45-62.		0
391	Recent progress in the development of immunotherapy for melanoma. <i>Skin Cancer</i> , 2004, 19, 25-33.	0.1	0

#	ARTICLE	IF	CITATIONS
392	Problems of and directions in improving immunotherapy for melanoma. <i>Skin Cancer</i> , 2004, 19, 306-312.	0.1	0
393	Harnessing T-Cell Immunity to Target Brain Tumors. , 2009, , 1165-1217.		3
394	Targeting Cancer with Amino-Acid Auxotroph <i>Salmonella typhimurium</i> A1-R. , 2012, , 209-223.		0
395	Therapeutic vaccines based on genetically modified <i>Salmonella</i> : a novel strategy in cancer immunotherapy. <i>Polish Archives of Internal Medicine</i> , 2011, 121, 461-467.	0.3	8
396	New Breast Cancer Treatment Considerations: A Brief Review of the Use of Genetically Modified (Attenuated) Bacteria as Therapy for Advanced and Metastatic Breast Cancer. , 2013, , 363-371.		0
397	Bacteria-Based Vectors for Oral Gene Therapy. , 2014, , 313-324.		0
398	Bacterial Cancer Therapy: How Patients Might Benefit from <i>Salmonella</i> Infections. , 2015, , 335-376.		0
399	Methods for Tumor Targeting with <i>Salmonella typhimurium</i> A1-R. <i>Methods in Molecular Biology</i> , 2016, 1409, 143-164.	0.4	1
400	Factors Affecting Bacterial Propagation towards Tumor Microenvironments. <i>MOJ Proteomics & Bioinformatics</i> , 2016, 4, .	0.1	0
401	Shaping cancerous landscapes with microbial communities. <i>Postdoc Journal</i> , 2016, 4, .	0.4	0
402	Microwave ablation combined with attenuated <i>Salmonella typhimurium</i> for treating hepatocellular carcinoma in a rat model. <i>Oncotarget</i> , 2017, 8, 47655-47664.	0.8	0
403	Positive and Negative Effects of the Commensal Bacteria on Carcinogenesis. <i>Sudan Journal of Medical Sciences</i> , 0, , .	0.3	0
404	The Molecular Approach behind Biotechnological Common Problems. <i>Journal of Biotechnology & BioResearch</i> , 2019, 2, .	0.0	0
406	Bacterial cancer therapy in autochthonous colorectal cancer affects tumor growth and metabolic landscape. <i>JCI Insight</i> , 2021, 6, .	2.3	4
407	Bacterial Systems for Tumor-Specific Gene Therapy. , 2005, , 393-404.		0
408	Evaluations of CRC2631 toxicity, tumor colonization, and genetic stability in the TRAMP prostate cancer model. <i>Oncotarget</i> , 2020, 11, 3943-3958.	0.8	0
410	<i>Fusobacterium nucleatum</i> enhances the efficacy of PD-L1 blockade in colorectal cancer. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 398.	7.1	84
411	Aptamer-assisted tumor localization of bacteria for enhanced biotherapy. <i>Nature Communications</i> , 2021, 12, 6584.	5.8	85

#	ARTICLE	IF	CITATIONS
412	The Evolution and Future of Targeted Cancer Therapy: From Nanoparticles, Oncolytic Viruses, and Oncolytic Bacteria to the Treatment of Solid Tumors. <i>Nanomaterials</i> , 2021, 11, 3018.	1.9	8
414	Dual Functionalized <i>Lactococcus lactis</i> Shows Tumor Antigen Targeting and Cytokine Binding in Vitro. <i>Frontiers in Bioengineering and Biotechnology</i> , 2022, 10, 822823.	2.0	3
415	Live attenuated bacterium limits cancer resistance to CAR-T therapy by remodeling the tumor microenvironment. , 2022, 10, e003760.		15
416	The impact of the human microbiome in tumorigenesis, cancer progression, and biotherapeutic development. <i>BMC Microbiology</i> , 2022, 22, 53.	1.3	25
417	Optimized Attenuated <i>Salmonella Typhimurium</i> Suppressed Tumor Growth and Improved Survival in Mice. <i>Frontiers in Microbiology</i> , 2021, 12, 774490.	1.5	10
419	Background-suppressed tumor-targeted photoacoustic imaging using bacterial carriers. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	14
420	A programmable encapsulation system improves delivery of therapeutic bacteria in mice. <i>Nature Biotechnology</i> , 2022, 40, 1259-1269.	9.4	89
421	Reprogramming Synthetic Cells for Targeted Cancer Therapy. <i>ACS Synthetic Biology</i> , 2022, 11, 1349-1360.	1.9	12
422	Advancement and Applications of Platelet-Inspired Nanoparticles: A Paradigm for Cancer Targeting. <i>Current Pharmaceutical Biotechnology</i> , 2022, 23, .	0.9	1
423	Bacteria-Based Synergistic Therapy in the Backdrop of Synthetic Biology. <i>Frontiers in Oncology</i> , 2022, 12, 845346.	1.3	3
424	Recent Update on Bacteria as a Delivery Carrier in Cancer Therapy: From Evil to Allies. <i>Pharmaceutical Research</i> , 2022, 39, 1115-1134.	1.7	9
425	Bacterial-Based Cancer Therapy (BBCT): Recent Advances, Current Challenges, and Future Prospects for Cancer Immunotherapy. <i>Vaccines</i> , 2021, 9, 1497.	2.1	38
426	Potential Utility of Induced Translocation of Engineered Bacteria as a Therapeutic Agent for Mounting a Personalized Neoantigen-Based Tumor Immune Response. <i>Global Challenges</i> , 2022, 6, 2100051.	1.8	0
427	Innovative Approaches of Engineering Tumor-Targeting Bacteria with Different Therapeutic Payloads to Fight Cancer: A Smart Strategy of Disease Management. <i>International Journal of Nanomedicine</i> , 2021, Volume 16, 8159-8184.	3.3	14
428	Pattern of F-18 FDG Uptake in Colon Cancer after Bacterial Cancer Therapy Using Engineered <i>Salmonella Typhimurium</i> : A Preliminary In Vivo Study. <i>Molecular Imaging</i> , 2022, 2022, 9222331.	0.7	2
430	Microbiota in health and diseases. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 135.	7.1	494
432	Macrophage-mediated tumor-targeted delivery of engineered <i>Salmonella typhimurium</i> VNP20009 in anti-PD1 therapy against melanoma. <i>Acta Pharmaceutica Sinica B</i> , 2022, 12, 3952-3971.	5.7	11
433	Engineering bacterial membrane nanovesicles for improved therapies in infectious diseases and cancer. <i>Advanced Drug Delivery Reviews</i> , 2022, 186, 114340.	6.6	16

#	ARTICLE	IF	CITATIONS
434	Intratumor microbiome in cancer progression: current developments, challenges and future trends. Biomarker Research, 2022, 10, .	2.8	25
435	Targeting primary and metastatic tumor growth in an aggressive breast cancer by engineered tryptophan auxotrophic Salmonella Typhimurium. Molecular Therapy - Oncolytics, 2022, 25, 350-363.	2.0	9
437	Current Status and Future Directions of Bacteria-Based Immunotherapy. Frontiers in Immunology, 0, 13, .	2.2	7
438	Chimeric adenoviral (Ad5.F35) and listeria vector prime-boost immunization is safe and effective for cancer immunotherapy. Npj Vaccines, 2022, 7, .	2.9	5
439	Intratumoral injection of schwannoma with attenuated <i>Salmonella typhimurium</i> induces antitumor immunity and controls tumor growth. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	12
440	Comparison of Anticancer Activities and Biosafety Between Salmonella enterica Serovar Typhimurium ΔppGpp and VNP20009 in a Murine Cancer Model. Frontiers in Microbiology, 0, 13, .	1.5	4
443	A SARS-CoV-2 oral vaccine development strategy based on the attenuated Salmonella type III secretion system. Journal of Applied Microbiology, 2022, 133, 2484-2500.	1.4	3
444	Salmonella-induced immune response reduces recurrence and tumor dissemination in preclinical melanoma model. Current Research in Immunology, 2022, 3, 159-166.	1.2	0
445	A rapid screening platform to coculture bacteria within tumor spheroids. Nature Protocols, 2022, 17, 2216-2239.	5.5	7
446	Flagellated bacterial porter for in situ tumor vaccine. Microbial Cell, 2022, 9, 158-161.	1.4	1
447	Do Bacteria Provide an Alternative to Cancer Treatment and What Role Does Lactic Acid Bacteria Play?. Microorganisms, 2022, 10, 1733.	1.6	4
448	Recombinant Attenuated Salmonella enterica as a Delivery System of Heterologous Molecules in Cancer Therapy. Cancers, 2022, 14, 4224.	1.7	10
449	Antitumor effect of <i>Escherichia coli</i> -derived outer membrane vesicles on neuroblastoma <i>in vitro</i> and <i>in vivo</i> . Acta Biochimica Et Biophysica Sinica, 2022, . .	0.9	3
450	Bacteria-mediated tumor-targeted delivery of tumstatin (54-132) significantly suppresses tumor growth in mouse model by inhibiting angiogenesis and promoting apoptosis. Frontiers of Medicine, 2022, 16, 873-882.	1.5	1
451	Targeted Depletion of Hyaluronic Acid Mitigates Murine Breast Cancer Growth. Cancers, 2022, 14, 4614.	1.7	3
452	Recent advances in bacterial therapeutics based on sense and response. Acta Pharmaceutica Sinica B, 2023, 13, 1014-1027.	5.7	4
453	Bacteria-mediated cancer therapy: A versatile bio-sapper with translational potential. Frontiers in Oncology, 0, 12, .	1.3	0
454	Designer Microbes: Oncotherapy Approach. , 2022, , 231-247.		0

#	ARTICLE	IF	CITATIONS
455	Recent advances in bacteria-mediated cancer therapy. <i>Frontiers in Bioengineering and Biotechnology</i> , 0, 10, .	2.0	7
456	Salmonella as a Promising Curative Tool against Cancer. <i>Pharmaceutics</i> , 2022, 14, 2100.	2.0	12
457	Enhancing Gasdermin-induced tumor pyroptosis through preventing ESCRT-dependent cell membrane repair augments antitumor immune response. <i>Nature Communications</i> , 2022, 13, .	5.8	44
458	Recent Advances in Bacteria-Based Cancer Treatment. <i>Cancers</i> , 2022, 14, 4945.	1.7	9
460	Anti-Tumor Effects of Engineered VNP20009-Abvec-Ig ^g -mPD-1 Strain in Melanoma Mice via Combining the Oncolytic Therapy and Immunotherapy. <i>Pharmaceutics</i> , 2022, 14, 2789.	2.0	2
461	Design of combination therapy for engineered bacterial therapeutics in non-small cell lung cancer. <i>Scientific Reports</i> , 2022, 12, .	1.6	2
462	Modification of bacterial cells for in vivo remotely guided systems. <i>Frontiers in Bioengineering and Biotechnology</i> , 0, 10, .	2.0	0
464	Manipulating the Gut Microbiome as a Therapeutic Strategy to Mitigate Late Effects in Childhood Cancer Survivors. <i>Technology in Cancer Research and Treatment</i> , 2023, 22, 153303382211497.	0.8	1
465	Effect of Antibiotic Treatment on Attenuated <i>Salmonella typhimurium</i> VNP20009 Mediated Schwannoma Growth Control. <i>Anticancer Research</i> , 2023, 43, 1-6.	0.5	2
466	<it>Salmonella typhimurium</it> may support cancer treatment: a review. <i>Acta Biochimica Et Biophysica Sinica</i> , 2023, 55, 331-342.	0.9	2
467	Programming the lifestyles of engineered bacteria for cancer therapy. <i>National Science Review</i> , 2023, 10, .	4.6	8
468	Salmonella Typhimurium expressing chromosomally integrated Schistosoma mansoni Cathepsin B protects against schistosomiasis in mice. <i>Npj Vaccines</i> , 2023, 8, .	2.9	2
469	Bacterial-Mediated Tumor Therapy: Old Treatment in a New Context. <i>Advanced Science</i> , 2023, 10, .	5.6	5
470	Blautia coccoides JCM1395T Achieved Intratumoral Growth with Minimal Inflammation: Evidence for Live Bacterial Therapeutic Potential by an Optimized Sample Preparation and Colony PCR Method. <i>Pharmaceutics</i> , 2023, 15, 989.	2.0	1
471	Ectopic expression of cGAS in <i>Salmonella typhimurium</i> enhances STING-mediated IFN- ^g response in human macrophages and dendritic cells. , 2023, 11, e005839.		1